Aggregate Reporting

Periodic aggregate reporting to regulatory authorities throughout the drug life cycle

During the clinical development and for the entire life cycle of the drug, the sponsors/MAHs must submit the safety information to the regulatory authorities within the defined time intervals. This information will help companies and the regulators assess the overall risk-benefit profile of the product on a periodic basis. These timelines, frequency, and type of periodic reports vary by country.

Our team of experts ensures timely submission of high-quality periodic reports, safety summary updates, and risk assessment documents in the proper format with the appropriate clinical content.

The team is experienced in:

  • compilation of aggregate reports as per the regulatory requirements on a global basis
  • publishing of reports and preparation of submission packages (electronic common technical document [eCTD] format) and
  • electronic submissions to various regulatory authorities via submission portals.

The APCER Aggregate Reporting team will help you create and submit:

  • Periodic benefit-risk evaluation reports (PBRERs)
  • Periodic safety update reports (PSURs)
  • Periodic adverse drug experience reports (PADERs)
  • Addendum to clinical overview (ADCO) for renewal
  • Clinical expert statements (CESs)
  • Summary bridging reports (SBRs)
  • PSUR addendum reports (ARs)
  • Development safety update report (DSUR)
  • Annual safety report (ASR)
  • Annual investigational new drug (IND) safety report
  • Expert reports for renewals
  • Safety assessment reports

How can we work together for better health?

How can we work together for better health?

    Please note that by submitting this form, you consent to your personal data being processed in alignment with our Privacy Policy. APCER is committed to ensuring the security and protection of your personal information. Your personal data will be processed for purpose of facilitating your request and may be used for sending you additional marketing and business development-related information about APCER Life Sciences, its affiliates and our services. You can withdraw your consent by writing to us at